MDT

98.74

-1.06%↓

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

MDT

98.74

-1.06%↓

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

MDT

98.74

-1.06%↓

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

MDT

98.74

-1.06%↓

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

MDT

98.74

-1.06%↓

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

Home・Aktien・Cogent Biosciences Inc

Cogent Biosciences Inc

Geschlossen

35.34 -2.08

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

34.15

Max

35.98

Schlüsselkennzahlen
By Trading Economics
Einkommen	-7.4M -81M
EPS	-0.5
Angestellte	205
EBITDA	-6.8M -79M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+34.27% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	24. Feb. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	3.1B 5.3B
Vorheriger Eröffnungskurs	37.42
Vorheriger Schlusskurs	35.34

Technischer Score

By Trading Central

Vertrauen

Bearish Evidence

4.88 / 5.87 Unterstützung & Widerstand

Cogent Biosciences Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

8. Jan. 2026, 23:08 UTC

Akquisitionen, Fusionen, Übernahmen

Rio Tinto, Glencore in Talks to Form World's Biggest Miner -- 3rd Update

8. Jan. 2026, 21:39 UTC

Akquisitionen, Fusionen, Übernahmen

Glencore, Rio Tinto Restart Merger Talks -- 2nd Update

8. Jan. 2026, 20:54 UTC

Akquisitionen, Fusionen, Übernahmen

Glencore, Rio Tinto Restart Merger Talks -- Update

8. Jan. 2026, 20:44 UTC

Akquisitionen, Fusionen, Übernahmen

Glencore, Rio Tinto Restart Merger Talks

8. Jan. 2026, 17:05 UTC

Akquisitionen, Fusionen, Übernahmen

Chinese Anta Sports Products Offers to Buy Pinault Family's Stake in Puma, Reuters Says, Citing Unnamed Sources

8. Jan. 2026, 16:43 UTC

Wichtige Markttreiber

Babcock & Wilcox Shares Rise on Siemens Deal for Data Center Project

8. Jan. 2026, 23:44 UTC

Market Talk

Nikkei May Rise on Weaker Yen -- Market Talk

8. Jan. 2026, 23:37 UTC

Market Talk

Gold Steady, Underpinned by Geopolitical Risks -- Market Talk

8. Jan. 2026, 22:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8. Jan. 2026, 22:42 UTC

Market Talk

RBA Still Battling a Troubling Inflation Outlook, Says TD -- Market Talk

8. Jan. 2026, 22:30 UTC

Akquisitionen, Fusionen, Übernahmen

Glencore, Rio Tinto Confirm Early Merger Talks -- Barrons.com

8. Jan. 2026, 21:53 UTC

Ergebnisse

These Stocks Moved the Most Today: Lockheed, Northrop, Alphabet, Applied Digital, Bloom Energy, Neogen, and More -- Barrons.com

8. Jan. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

8. Jan. 2026, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

8. Jan. 2026, 21:10 UTC

Akquisitionen, Fusionen, Übernahmen

Rio Tinto Says Current Expectation That Any Deal Would Involve Buying Glencore Via Scheme of Arrangement

8. Jan. 2026, 21:09 UTC

Market Talk

Oil Rises As Trump Said to Back Russia Sanctions Bill -- Market Talk

8. Jan. 2026, 21:09 UTC

Akquisitionen, Fusionen, Übernahmen

Rio Tinto Confirms in Talks With Glencore Over Possible Merger

8. Jan. 2026, 20:21 UTC

Market Talk

U.S. Natural Gas Futures Down Despite Inventory Draw -- Market Talk

8. Jan. 2026, 19:44 UTC

Market Talk

Gold's Shine Masks Deep Drops in Canada Steel, Aluminum Exports -- Market Talk

8. Jan. 2026, 18:50 UTC

Market Talk

Mexico's Industrial Production Seen Lower in November -- Market Talk

8. Jan. 2026, 17:48 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Lockheed, Northrop, Alphabet, Applied Digital, Bloom Energy, Neogen, and More -- Barrons.com

8. Jan. 2026, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

8. Jan. 2026, 17:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

8. Jan. 2026, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

8. Jan. 2026, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

8. Jan. 2026, 16:45 UTC

Market Talk

Goldman Lifts 1H LME Copper Forecast -- Market Talk

8. Jan. 2026, 16:03 UTC

Market Talk

Global Equities Roundup: Market Talk

8. Jan. 2026, 16:03 UTC

Market Talk

Currency Markets Could Be Underpricing Medium-Term Risks -- Market Talk

8. Jan. 2026, 16:02 UTC

Market Talk

U.S. Natural Gas Inventories Fall As Expected -- Market Talk

8. Jan. 2026, 15:23 UTC

Akquisitionen, Fusionen, Übernahmen

Paramount Defends Its Hostile Bid for Warner -- Update

Peer-Vergleich

Kursveränderung

Cogent Biosciences Inc Prognose

Kursziel

By TipRanks

34.27% Vorteil

12-Monats-Prognose

Durchschnitt 48.7 USD 34.27%

Hoch 67 USD

Tief 34 USD

Basierend auf 11 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Cogent Biosciences Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

11 ratings

Buy

Halten

Sell

Basierend auf 11 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Cogent Biosciences Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

4.88 / 5.87Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.